Acute Post-Streptococcal Glomerulonephritis in the Northern Territory of Australia: A Review of Data from 2009 to 2016 and Comparison with the Literature

Swasti Chaturvedi, 1 Rowena Boyd, 2 and Vicki Krause 2*

1 Department of Paediatrics, Royal Darwin Hospital, Darwin, Australia; 2 Department of Health, Centre for Disease Control, Darwin, Australia

Abstract. Acute post-streptococcal glomerulonephritis (APSGN) is an inflammatory kidney disease following infection with nephritogenic strains of Group A Streptococcus. In 1991, APSGN became notifiable in the Northern Territory (NT) of Australia with cases recorded on the NT Notifiable Disease Database (NTNDS). The case definition of a confirmed case requires laboratory definitive evidence or laboratory suggestive evidence in conjunction with a clinically compatible illness. Probable cases require clinical evidence only. Acute post-streptococcal glomerulonephritis notifications from 2009 to 2016 were extracted from the NTNDS. Of the 322 cases, 261 were confirmed and 61 probable. The majority, 304 (94%), were Aboriginal and the median age was 8 years (range: 0–62 years). Incidence for confirmed cases was 13.8/100,000 person-years, with inclusion of probable cases increasing incidence to 17.0/100,000 person-years. Highest incidence of confirmed cases was in Aboriginal children less than 15 years of age at 124.0 cases/100,000 person-years. The rate ratio of confirmed cases in Aboriginal to non-Aboriginal Australians was 18.9 (95% confidence interval: 11.4–33.6). Recent trends show a consistently high number of notifications annually with less frequent outbreaks. The Aboriginal population of the NT continues to have high rates of APSGN with recent trends showing higher rates than previously reported. Sustained preventative efforts and continued surveillance strategies are needed.

INTRODUCTION

Aboriginal Australians suffer one of the highest rates of chronic kidney disease (CKD) in the world. 1 Acute post-streptococcal glomerulonephritis (APSGN) is an inflammatory kidney disease caused by prior infection with nephritogenic strains of Group A Streptococcus (GAS). Previous work by Hoy et al. 2 reported APSGN as a major risk factor for the development of CKD in the Australian Aboriginal population living in remote communities.

Recognition of the heavy burden of disease in the Northern Territory (NT) led to establishment of case definitions, mandatory clinician notification of disease, and establishment of an APSGN database in 1991. The purpose of notification includes facilitating accurate disease monitoring and directed public health response. The confirmed case requires either laboratory definitive evidence (renal biopsy suggestive of APSGN) or the presence of both laboratory suggestive evidence and clinical evidence (Table 1). A contact is defined as those staying in the house in the 2 weeks preceding the onset of the illness.

The epidemiology of APSGN in the NT from 1991 to 2008 has previously been reported. 3 This article describes the epidemiology of APSGN in the NT from 2009 to 2016 and identifies trends. A review of the literature enables a comparison of NT disease burden against global trends.

METHODS

Setting. In 2016, the estimated resident population in the NT was 228,833. 4 Aboriginal Australians constitute approximately 30% of the population, and 80% of the NT Aboriginal population live in remote or very remote locations. The Top End of the NT has two seasons: the cooler dry season which runs from April to September and the hot, rainy, and humid wet season from October to March. In Central Australia, there is a desert climate with intermittent rain throughout the year and cooler weather from April to September (mean temperature range 4–28°C) than the months of October to March (mean temperature range 15–36°C). 5

Epidemiological data. Data were collected as previously described, with the period of study identified from notifications between 1991 and 2016. 6 This study concentrates on describing post-2008 data, a previously undescribed period. Table 1 describes the case definition of a confirmed and probable case. Reoccurrence of disease was identified through matching at least two of the following notification fields including first name, surname, and date of birth. An outbreak year was declared if the number of notifications in the NT for a particular year more than doubled the mean number of notifications for the preceding 4 years.

Ethics approval. Ethics approval was obtained from the Human Research Ethics Committee, Menzies School of Health Research. HREC 2017-2914.

Statistical analysis. Population data for incidence calculations were obtained from the Australian Bureau of Statistics and NT Department of Health Analysis and reported as a rate per 100,000 person-years. Unless stated otherwise, calculations for incidence were based on confirmed cases only.

Review criteria. We searched Medline, Ebsco, and Pubmed using the terms (glomerulonephritis AND (strep OR streptococcal OR post-streptococcal OR poststreptococcal OR Group A Strept)) AND (studies OR study). The search was restricted to articles published in English language after 1965. We also searched reference lists of nephrology textbooks, review articles, and all articles and relevant reviews identified.
Laboratory evidence has been observed since 2008 (Figure 1). Previous yearly outbreaks before 2006 have not been evident in recent years. An outbreak of 76 notifications occurred in 2014. Indeed, the subclinical cases are thought to be 4–19 times more common than symptomatic disease.25,26 Thus, we assume that incidence is higher than reported.

**RESULTS**

**Northern Territory data.** Between 2009 and 2016, there were 261 confirmed and 61 probable cases of APSGN for a total of 322 cases. Characteristics of notifications are shown in Table 2, with most of the cases in Aboriginal Australians (304/322, 94%) and those less than 15 years of age (277/322; 86%). Median age was 8 years, with an interquartile range of 1–44 years including one infant less than 12 months diagnosed at 11 months.

For non-outbreak years, an upward trend in annual notifications has been observed since 2008 (Figure 1). Previous trends of five yearly outbreaks before 2006 have not been evident in recent years. An outbreak of 76 notifications occurred in 2014. The frequency and incidence of APSGN notifications by age group are shown in Figure 2. Highest incidence of APSGN was observed in Aboriginal children less than 15 years of age, with 124.0 (95% confidence interval [CI]: 108.4–141.2) cases per 100,000 (Table 3). For non-Aboriginal children less than 15 years of age, annualized incidence was 7.4 (95% CI: 3.7–10.6) cases per 100,000, resulting in an incidence rate ratio of 18.9 (95% CI: 11.4–33.6).

Notifications in the Top End (tropical climate) were similar, regardless of seasons with 116/213 (54%) notifications occurring in the dry season, April–September (95% CI: 48–61%) (Figure 3). In Central Australia (semiarid climate), notifications were significantly higher during the months April–September, with 69/109 (63%) cases occurring during these winter months (95% CI: 54–72%).

Between 1991 and 2016, there were 10 people reported with a second episode of APSGN. Time between diagnoses ranged from 210 days to 7 years (mean 4 years). During the same period, two sets of twins were notified with APSGN, with a difference of 6 and 10 days between diagnosis dates for the respective twin.

**Literature review.** We found 15 studies reporting data on incidence of APSGN as shown in Table 4. Highest incidence was reported among Aboriginal Australians aged < 15 years (239 per 100,000)9 and the lowest in an Italian study (0.09 per 100,000).10

**DISCUSSION**

The prognosis of APSGN is relatively benign in the low-risk populations; however, it is associated with a 5- to 6-fold increased risk of CKD in resource-limited settings.2,21 The incidence of APSGN has declined globally in the past four decades and particularly in some developed countries.10,17 Acute post-streptococcal glomerulonephritis, however, remains an important health problem in developing countries and tropical regions of a number of developed countries. Some developing countries report APSGN as the most common cause of acute nephritis.22,23 Carapetis et al. analyzed data from 11 population-based studies and calculated the annual incidence of APSGN as ranging from 6 to 24.3 per 100,000 person-years in the more developed to the less developed countries; however, it is associated with a 5- to 6-fold increased risk of CKD in resource-limited settings.2,21 The true incidence of the disease is difficult to determine because of the under-recognition of the milder cases of APSGN and the transient nature of the illness. Indeed, the subclinical cases are thought to occur 4–19 times more common than symptomatic disease.25,26 Thus, we assume that incidence is higher than reported.

**Table 2**

| Characteristic | Total 322 | % |
|---------------|----------|---|
| Aboriginal    | 304      | 94% |
| Non-Aboriginal | 18       | 6% |
| Age (years)   |          |    |
| 0–4           | 93       | 29% |
| 5–9           | 115      | 36% |
| 10–14         | 69       | 21% |
| 15–19         | 10       | 3% |
| Older than 19 | 10       | 3% |
| Male          | 178      | 55% |
| Hospitalized  | 280/304* | 92% |

*Denominator only available for 304 cases.

**Table 3**

| Age (years) | 1992–2007 (95% CI) | 2009–2016 (95% CI) |
|-------------|-------------------|-------------------|
| All ages    | 12.5 (11.3–13.8)  | 13.8 (12.1–15.5)  |
| 0–14        | 41.4 (37.0–46.1)  | 56.9 (50.0–64.5)  |
| > 14        | 2.1 (1.6–2.6)     | 1.2 (0.7–1.9)     |
| Aboriginal  | 39.7 (35.7–44.0)  | 43.6 (38.3–49.4)  |
| 0–14        | 49.4 (42.4–56.3)  | 124.0 (108.4–141.2) |
| > 14        | 7.3 (5.3–9.9)     | 4.8 (2.8–7.5)     |
| Non-Aboriginal | 0.74 (0.42–1.2) | 1.2 (0.7–1.9) |
| 0–14        | 2.3 (1.2–4.2)     | 6.6 (3.7–10.6)    |
| > 14        | 0.30 (0.095–0.69) | 0 (0.0–0.3)       |

CI = confidence interval.

APSGN = acute post-streptococcal glomerulonephritis.
Marshall et al.\textsuperscript{3} have previously reported 16 years data on APSGN from the NT of Australia. They reported 415 confirmed cases and 23 probable cases during the study period of 1991 to July 2008. The current data reveal that the NT of Australia continues to have a heavy burden of APSGN with 261 confirmed and 61 probable cases between 2009 and 2016.

Incidence in children less than 15 years of age has significantly increased in both Aboriginal and non-Aboriginal children. Before 2009, Marshall et al. identified an incidence in Aboriginal children less than 15 years of age at 94.3 per 100,000 person-years (95% CI: 84.2–105.3) compared with our more recent finding of 124.0 person-years (95% CI: 108.4–141.2). In non-Aboriginal children, incidence has increased from 2.3 (95% CI: 1.2–4.2) for the 1991–2008 period to 6.6 (95% CI: 3.7–10.6) cases per 100,000. It is not known if there is a real increase in the number of cases or greater reporting of cases. Interestingly, the Aboriginal to non-Aboriginal rate ratio in the same age group has significantly decreased from 53.6 (95% CI: 32.6–94.8) to 18.9 (95% CI: 11.4–33.6) pre- and post-2009. We do not know if this decreasing gap between disease burden in Aboriginal and non-Aboriginal children represents greater burden of disease in non-Aboriginal children or greater identification and reporting of APSGN in this population.

The previous trends of five yearly outbreaks are not evident since 2005, with the outbreak in 2014 “overdue,” occurring 9...
years after the previous outbreak of 98 cases in 2005. Rather, recent trends show a consistently higher number of notifications annually with less frequency of outbreaks. Not enough time has elapsed to determine if this is a long-term trend.

The seasonal variation noted in the present study contrasts with that reported by Marshall et al.\(^3\) Previously, Central Australia had similar frequency of cases across winter/summer seasons, whereas the Top End had significantly more during the dry season than the wet. Since 2009, the trend has reversed, indicating APSGN may not be reliably associated with seasonality in the NT.

Our study indicates that even though APSGN incidence has declined substantially around the world, there remains a high disease burden among the Aboriginal population in NT.\(^6,18,27,28\) Group A streptococcal infection and its sequelae diseases represent social disadvantage, poverty, remoteness,

### Table 4

| Study (reference number) | Age group (years) | Period of study | Country | APSGN incidence (per 100,000 per year) |
|--------------------------|-------------------|-----------------|---------|--------------------------------------|
| Present study            | All ages          | 2009–2016       | NT, Australia | Overall: 17.0  |
|                          |                   |                 |         | Aboriginal < 15 years of age: 155.1  |
|                          |                   |                 |         | Non-Aboriginal < 15 years of age: 7.4 |
| Wong et al.\(^{18}\)     | < 14              | 2007–2009       | New Zealand | Overall: 9.7   |
|                          |                   |                 |         | Pacific Islander: 45.5               |
|                          |                   |                 |         | Maori: 15.7                       |
|                          |                   |                 |         | European/other: 2.6                  |
| Marshall et al.\(^3\)   | All ages          | 1991–2008       | NT, Australia | Overall: 12.5 |
|                          |                   |                 |         | Aboriginal < 15 years of age: 94.3   |
|                          |                   |                 |         | Non-Aboriginal < 15 years of age: 2.3 |
| Becquet et al.\(^7\)    | < 15              | 2005–2007       | French Polynesia | 18                |
| Berrios et al.\(^8\)    | < 15              | 1980–1999       | Chile    | 1980–1983: 6.2  |
|                          |                   |                 |         | 1984–1989 (epidemic outbreak): 13.2  |
|                          |                   |                 |         | 1990–1999: 1.7  |
| Herrera and Rodríguez-Iturbe\(^{12}\) | All ages         | 1991–1998       | Venezuela | Goajiro Indians: 2.9  |
| Muscatello et al.\(^{16}\) | < 20             | 1989–1998       | New South Wales, Australia | 2.2  |
| Baker et al.\(^9\)      | 5–14              | 1988–1998       | New Zealand | Maori: 48  |
|                          |                   |                 |         | Pacific Islander: 80            |
| Carapetis\(^9\)         | < 15              | 1993–1995       | NT, Australia | Aboriginal: 239;  |
|                          |                   |                 |         | Non-Aboriginal: 6   |
| Coppo et al.\(^{10}\)   | All ages          | 1998            | Italy    | < 60 years: 0.04    |
|                          |                   |                 |         | > 60 years: 0.09     |
| Eke and Eke\(^{11}\)    | < 15              | 1986–1991       | Nigeria  | 24.3                  |
| Simon et al.\(^{17}\)   | All ages          | 1986–1990       | France  | 0.15                  |
| Yap et al.\(^{19}\)     | < 12              | 1985            | Singapore | 10.8  |
| Lennon et al.\(^{14}\)  | Children          | 1981–1984       | New Zealand | Maori: 50.5  |
|                          |                   |                 |         | Pacific Islander: 46.5|
|                          |                   |                 |         | Other: 5.9            |
| Majeed et al.\(^{15}\)  | Children          | 1980–1983       | Kuwait  | 17.8                  |
| Khuffash et al.\(^{13}\) | Children          | 1980–1984       | Kuwait  | 19.5                  |

\(^{APSGN} = \text{acute post-streptococcal glomerulonephritis; NT = Northern Territory.}\)
and overcrowding. Multiple approaches have been used in the past to tackle GAS infections and their sequelae with varying degrees of success. These include setting up community health-care programs that focus on prevention of skin diseases, establishing APSGN as a notifiable disease with subsequent public health action, and for acute rheumatic fever/rheumatic heart disease prevention providing secondary prophylaxis with long-acting penicillins. The reduction in worldwide prevalence of APSGN has coincided with improvement in living conditions and use of benzathine penicillin chemoprophylaxis for streptococcal pharyngitis in closed adult populations.

Further planning is needed to build capacity in Aboriginal communities with community workers and clinicians to reduce the burden of GAS infection, to enhance data collection to look carefully at long-term outcomes of APSGN, and work to improve living conditions of the Aboriginal population. A multipronged approach to control GAS infection with improved hygiene, education, and living conditions of Aboriginal populations along with continued research into vaccine development is needed.

Received February 1, 2018. Accepted for publication August 21, 2018.

Published online November 5, 2018.

Acknowledgment: Peter Morris-Menzies School of Health Research.

Authors’ addresses: Swasti Chaturvedi, Department of Paediatrics, Royal Darwin Hospital, Darwin, Australia, E-mail: swasti.chaturvedi@gmail.com. Rowena Boyd and Vicki Krause, Department of Health, Centre for Disease Control, Darwin, Australia, E-mails: rowena.boyd@nt.gov.au and vicki.krause@nt.gov.au.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

REFERENCES

1. McDonald SP. 2013. End-stage kidney disease among indigenous peoples of Australia and New Zealand. Kidney Int Suppl 3: 170–173.

2. Hoy WE, White AV, Dowling A, Sharma SK, Bloomfield H, Tiploura BT, Swanson CE, Mathews JD, McCredie DA, 2012. Post-streptococcal glomerulonephritis is a strong risk factor for chronic kidney disease in later life. Kidney Int 81: 1026–1032.

3. Marshall CS, Cheng AC, Markey PG, Towers RJ, Richardson LJ, Fagan PK, Scott L, Krause VL, Currie BJ, 2011. Acute poststreptococcal glomerulonephritis in the Northern Territory of Australia: a review of 16 years data and comparison with any medium, provided the original author and source are credited.

4. Australian Bureau of Statistics, 2017. 2016 Census Reveals the Changing Face of the Northern Territory. Available at: http://www.abs.gov.au/ausstats/abs@.nsf/mf/4102.0.

5. Bureau of Meteorology, 2018. Climate Statistics for Australian Locations. Available at: http://www.bom.gov.au/climate/averages/tables/cw_015590_All.shtml. Accessed July 22, 2018.

6. Baker M, Naing T, Martin D, Crampton B, 2000. The Comparative Epidemiology of Post Streptococcal Diseases in New Zealand: Acute Rheumatic Fever and Acute Glomerulonephritis in streptococci and streptococcal diseases: Entering the New Millennium. Porirua, New Zealand: ESR, Porirua, 545–547.

7. Becquet O, Pasche J, Gatti H, Chenel C, Abély M, Morville P, Pietrement C, 2010. Acute post-streptococcal glomerulonephritis in children of French Polynesia: a 3-year retrospective study. Pediatr Nephrol 25: 275–280.

8. Berrios X, Lagomarsino E, Solar E, Sandoval G, Guzman B, Riedel I, 2004. Post-streptococcal acute glomerulonephritis in Chile—20 years of experience. Pediatr Nephrol 19: 306–312.

9. Carapetis JR, 1998. Ending the Heartache: The Epidemiology and Control of Acute Rheumatic Fever and Rheumatic Heart Disease in the Top End of the Northern Territory, Sydney, Australia: University of Sydney.

10. Coppo R, Gianoglio B, Porcellini MG, Maringhini S, 1998. Frequency of renal diseases and clinical indications for renal biopsy in children (report of the Italian National Registry of Renal Biopsies in Children). Group of Renal Immunopathology of the Italian Society of Pediatric Nephrology and Group of Renal Immunopathology of the Italian Society of Nephrology. Nephrol Dial Transplant 13: 293–297.

11. Eke FU, Eke NN, 1994. Renal disorders in children: a Nigerian study. Pediatr Nephrol 8: 383–386.

12. Herrera J, Rodríguez-Iturbe B, 2003. End-stage renal disease and acute glomerulonephritis in Goajiro Indians. Kidney Int Suppl 62: S22–S26.

13. Khuffash FA, Sharda DC, Majeed HA, 1986. Sporadic pharyngitis-associated acute poststreptococcal nephritis. A four-year prospective clinical study of the acute episode. Clin Pediatr (Phila) 25: 181–184.

14. Lennon D, Martin D, Wong E, Taylor LR, 1988. Longitudinal study of poststreptococcal disease in Auckland; rheumatic fever, glomerulonephritis, epidemiology and M typing 1981–86. N Z Med J 101: 396–398.

15. Majeed HA, Khuffash FA, Sharda DC, Farwana SS, el-Sherbiny AF, Ghafour SY, 1987. Children with acute rheumatic fever and acute poststreptococcal glomerulonephritis and their families in a subtropical zone: a three-year prospective comparative epidemiological study. Int J Epidemiol 16: 561–568.

16. Muscatelli DJ, O’Grady KA, Neville K, McAnulty J, 2001. Acute poststreptococcal glomerulonephritis: public health implications of recent clusters in New South Wales and epidemiology of hospital admissions. Epidemiol Infect 126: 365–372.

17. Simon P, Rame M-P, Autuly V, Laruelle E, Charasse C, Cam G, Ang KS, 1994. Epidemiology of primary glomerular diseases in a French region. Variations according to period and age. Kidney Int 46: 1192–1198.

18. Wong W, Lennon DR, Crone S, Neuteuf JM, Reed PW, 2013. Prospective population-based study on the burden of disease from post-streptococcal glomerulonephritis of hospitalised children in New Zealand: epidemiology, clinical features and complications. J Paediatr Child Health 49: 850–855.

19. Yap HK, Chia KS, Murugasu B, Saw AH, Tay JS, Ikhvanamn M, Tan KW, Cheng HK, Tan CL, Lim CH, 1990. Acute glomerulonephritis—changing patterns in Singapore children. Pediatr Nephrol 4: 482–484.

20. Jackson SJ, Steer AC, Campbell H, 2011. Systematic review: estimation of global burden of nonsuppurative sequelae of upper respiratory tract infection: rheumatic fever and poststreptococcal glomerulonephritis. Trop Med Int Health 16: 2–11.

21. Pinto SW, Mastroianni-Kirsztajn G, Sesso R, 2015. Ten-year follow-up of patients with epidemic post infectious glomerulonephritis. PLoS One 10: e0125313.

22. Gunasekaran K, Krishnamurthy S, Mahadevan S, Harish BN, Kumar AP, 2015. Clinical characteristics and outcome of post-infectious glomerulonephritis in children in southern India: a prospective study. Indian J Pediatr 82: 896–903.

23. Stratta P, Musetti C, Barreca A, Mazzucco G, 2014. New trends of an old disease: the acute post infectious glomerulonephritis at the beginning of the new millenium. J Nephrol 27: 229–239.

24. Carapetis JR, Steer AC, Mulholland EK, Weber M, 2005. The global burden of group A streptococcal diseases. Lancet Infect Dis 5: 685–694.

25. Dodwe WF, Spargo BH, Travis LB, 1967. Occurrence of acute glomerulonephritis in siblings of children with sporadic acute glomerulonephritis. Pediatrics 40: 1028–1030.

26. Rodríguez-Iturbe B, Rubio L, García R, 1981. Attack rate of poststreptococcal nephritis in families. A prospective study. Lancet 1: 401–403.
27. Roy S 3rd, Stapleton FB, 1990. Changing perspectives in children hospitalized with poststreptococcal acute glomerulonephritis. *Pediatr Nephrol* 4: 585–588.
28. Zhang Y, Shen Y, Feld LG, Stapleton FB, 1994. Changing pattern of glomerular disease at Beijing Children’s Hospital. *Clin Pediatr* 33: 542–547.
29. Steer AC, Carapetis JR, Nolan TM, Shann F, 2002. Systematic review of rheumatic heart disease prevalence in children in developing countries: the role of environmental factors. *J Paediatr Child Health* 38: 229–234.
30. Bowen AC, Tong SY, Andrews RM, O’Meara IM, McDonald Ml, Chatfield MD, Currie BJ, Carapetis JR, 2014. Short-course oral co-trimoxazole versus intramuscular benzathine benzylpenicillin for impetigo in a highly endemic region: an open-label, randomised, controlled, non-inferiority trial. *Lancet* 384: 2132–2140.
31. Kearns TM et al., 2015. Impact of an ivermectin mass drug administration on scabies prevalence in a remote Australian aboriginal community. *PLoS Negl Trop Dis* 30: e0004151.
32. Krause V, Johnston F, 2010. *Northern Territory Guidelines for Acute Post-Streptococcal Glomerulonephritis*. Available at: http://digitallibrary.health.nt.gov.au/prodjspsui/handle/10137/444. Accessed July 22, 2018.
33. Wyber R, Taubert K, Marko S, Kaplan EL, 2013. Benzathine penicillin G for the management of RHD: concerns about quality and access, and opportunities for intervention and improvement. *Glob Heart* 8: 227–234.
34. Eison TM, Ault BH, Jones DP, Chesney RW, Wyatt RJ, 2011. Post-streptococcal acute glomerulonephritis in children: clinical features and pathogenesis. *Pediatr Nephrol* 26: 165–180.
35. Gunzenhauser JD, Longfield JN, Brundage JF, Kaplan EL, Miller RN, Brandt CA, 1995. Epidemic streptococcal disease among Army trainees, July 1989 through June 1991. *J Infect Dis* 172: 124–131.
36. May PJ, Bowen AC, Carapetis JR, 2016. The inequitable burden of group A streptococcal diseases in indigenous Australians. *Med J Aust* 205: 201–203.
37. Rodriguez-Iturbe B, Musser JM, 2008. The current state of poststreptococcal glomerulonephritis. *J Am Soc Nephrol* 19: 1855–1864.